Patient safety is the top priority, and we will carefully evaluate all available evidence.
In an era when a single drug class has reshaped cultural conversations about body, appetite, and identity, Britain's medicines regulator has paused to ask a harder question: at what cost to the mind? The MHRA has opened a formal safety review of GLP-1 receptor agonists — including the widely celebrated Ozempic and Wegovy — following reports of suicidal thoughts and self-harm among patients, mirroring a parallel inquiry already underway across Europe. With millions taking these medications, often beyond their original approved purpose, the investigation asks society to weigh the visible promise of rapid transformation against risks that may be less visible but no less serious.
- Five adverse reports linking semaglutide to suicidal or self-injurious behavior since 2020 were enough to trigger a formal UK regulatory review — a small number that carries an outsized warning.
- The probe lands at a moment of peak cultural saturation: Ozempic is prescribed off-label across Britain, celebrated by influencers, and taken by millions who were never part of the original diabetic patient population it was designed to serve.
- European regulators moved first after Iceland flagged three cases of suicidal ideation, and the UK followed within two weeks — signaling that health authorities on both sides of the Channel are treating the signal as credible rather than coincidental.
- Manufacturers including Novo Nordisk, Eli Lilly, and Sanofi have acknowledged the review and pledged cooperation, though none have indicated their own internal safety monitoring raised comparable alarms.
- No timeline exists for the review's conclusion, leaving patients and prescribing doctors in a state of unresolved uncertainty — continuing to use medications whose full risk profile is still being written.
Britain's drug regulator has opened a formal investigation into GLP-1 receptor agonists — the class of medications that includes Ozempic and Wegovy — after receiving reports that some patients experienced suicidal thoughts or self-harm urges while taking them. The MHRA announced the review following a similar probe launched by European authorities just two weeks prior, after Iceland flagged three cases of suicidal ideation among patients on these drugs.
Ozempic was originally developed for Type 2 diabetes but has become a cultural phenomenon as an off-label weight-loss treatment. It works by mimicking the GLP-1 hormone, signaling fullness to the brain and suppressing appetite. Wegovy contains the same active ingredient — semaglutide — but carries formal approval for weight management. The review also covers liraglutide-based drugs and other GLP-1 medications from Eli Lilly, AstraZeneca, and Sanofi.
The MHRA has logged five adverse reports linking semaglutide to suicidal or self-injurious behavior since 2020, and twelve involving liraglutide dating back to 2010. Chief safety officer Dr. Alison Cave emphasized that all available evidence will be carefully evaluated before any guidance is issued. The review began July 12 with no announced end date. All major manufacturers have acknowledged the inquiry; Sanofi stated its own monitoring systems had not raised concerns.
The mental health questions arrive alongside a growing catalog of physical side effects — gastroparesis, blurred vision, kidney problems, and gallstones among them. Social media has surfaced stranger phenomena too: vivid celebrity dreams, dramatic finger and wrist shrinkage prompting a surge in jewelry resizing, and fat loss in areas patients had surgically enhanced.
The investigation marks a reckoning for drugs that have outpaced their original regulatory boundaries. As British and European authorities work to determine whether the psychiatric risks are real and how widespread they may be, the question facing patients and doctors is no longer simply whether these medications work — but whether the full weight of their consequences is yet understood.
Britain's drug regulator has opened a formal investigation into a class of medications that have become synonymous with rapid weight loss, after receiving reports that some patients experienced suicidal thoughts or urges toward self-harm while taking them. The Medicines and Healthcare Products Regulatory Agency announced the review on Tuesday, examining GLP-1 receptor agonists—a family of drugs that includes Ozempic and Wegovy, both made by Novo Nordisk, as well as competing medications from Eli Lilly, AstraZeneca, and Sanofi. The move follows a similar probe launched by European regulators just two weeks earlier, after Iceland's health authority flagged three cases of patients on these drugs who reported suicidal ideation.
Ozempic was originally developed to treat Type 2 diabetes, but it has exploded in popularity as an off-label weight-loss treatment, particularly among celebrities and social media influencers. The drug works by mimicking a natural hormone called GLP-1, which signals the brain that the stomach is full, causing people to eat less and lose weight rapidly. Wegovy is the same active ingredient—semaglutide—but approved specifically for weight management. Novo Nordisk's older drug Saxenda, which contains a different GLP-1 agonist called liraglutide, is also under review, as are several other medications in the same drug class used primarily for diabetes control.
The British regulator said it has received five adverse reports involving semaglutide linked to suicidal or self-injurious behavior since 2020, and twelve reports involving liraglutide with similar associations dating back to 2010. Dr. Alison Cave, the agency's chief safety officer, stated that patient safety is the top priority and that the agency will carefully evaluate all available evidence before issuing guidance to patients and doctors. The formal review began on July 12, though no timeline has been announced for when it might conclude or what findings it might produce. The investigation will examine adverse drug reactions reported directly by healthcare providers and patients.
All the major manufacturers involved have acknowledged the review. Sanofi told Reuters it is cooperating with the regulator and that its own safety monitoring systems have not identified concerns. Eli Lilly said it is aware of the investigation and will respond through routine regulatory channels. Novo Nordisk, whose drugs are at the center of the inquiry, received the formal request for review on Monday.
Beyond the mental health concerns, doctors and patients have reported a widening array of side effects from these medications. Some users have developed severe gastroparesis, a condition in which food moves abnormally slowly through the digestive system, leading to urgent and sometimes involuntary bowel movements. Others have reported blurred vision, kidney problems, and gallstones. The drugs have also triggered unusual phenomena on social media: patients sharing vivid, bizarre dreams involving celebrities, and a phenomenon dubbed "Ozempic finger," in which fingers and wrists shrink noticeably—so much so that jewelers report a 150 percent increase in women coming in to resize their rings and bracelets. Some users have complained of "sulfur burps" with a rotten-egg smell, and others have reported significant loss of fat in the buttocks, even among those who had undergone cosmetic enhancement surgery.
The investigation represents a critical moment for drugs that have become cultural phenomena, prescribed to millions worldwide for weight loss despite being approved for that purpose in only some cases. Ozempic in particular is used off-label for weight loss in Britain, meaning doctors prescribe it for a purpose the regulator did not originally authorize. As the British and European authorities examine whether the mental health risks are real and how common they might be, patients and doctors face uncertainty about whether these medications should continue to be used as freely as they have been, or whether new warnings and restrictions are warranted.
Citações Notáveis
Patient safety is our top priority. We will carefully consider all available evidence and communicate any further advice to patients and healthcare professionals as appropriate.— Dr. Alison Cave, chief safety officer, MHRA
Patient safety is Lilly's top priority, and we will respond to the review regarding safety signals related to dulaglutide as part of our routine regulatory review processes.— Eli Lilly, statement to Reuters
A Conversa do Hearth Outra perspectiva sobre a história
Why would a diabetes drug suddenly become the center of a mental health investigation?
Because it became wildly popular for weight loss—prescribed off-label to millions—and now regulators are getting reports of suicidal thoughts tied to it. Five cases in the UK since 2020 is small, but it's enough to trigger a formal look.
Is five cases a lot, or is that normal background noise for a drug this widely used?
That's the question regulators are trying to answer. They're looking at the actual rate of reports versus what you'd expect by chance. The fact that Europe launched a similar probe two weeks earlier suggests the signal is being taken seriously across multiple countries.
What's the mechanism? Why would a drug that makes you feel full cause suicidal thoughts?
Nobody knows yet. That's what the investigation is for. It could be direct—something about how the drug affects brain chemistry. Or indirect—rapid weight loss, body image changes, or the psychological shock of sudden physical transformation. Or it could be coincidence.
The article mentions a lot of other weird side effects—the dreams, the finger shrinking, the digestive chaos. Are those connected to the mental health issue?
Probably not directly. But they paint a picture of a drug that's affecting the body in ways we don't fully understand. When you're seeing this many unexpected effects, it makes you wonder what else might be happening that we haven't noticed yet.
What happens next?
The regulator reviews all the data, talks to the manufacturers, and decides whether to issue new warnings, restrict who can take it, or pull it from the market. But there's no timeline, and the outcome is completely unknown. In the meantime, millions of people are still taking it.
So patients are in limbo.
Exactly. They don't know if their medication is safe, their doctors don't know what to advise, and the companies are cooperating with regulators while maintaining that their safety systems haven't found problems. It's a very modern regulatory moment—a drug that's everywhere, working for weight loss, but with a growing list of questions nobody can answer yet.